Similar Articles |
|
The Motley Fool May 7, 2009 Brian Orelli |
Derailed and Built to Stay That Way Investors aren't happy with Biovail's plan to get back on track. |
The Motley Fool October 29, 2007 Brian Orelli |
The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note. |
The Motley Fool November 21, 2007 Brian Orelli |
Depression Hits Biovail An FDA decision on Biovail's depression drug could be another six months away. |
The Motley Fool September 23, 2008 Brian Orelli |
Extended Look at an Extended-Release Drug The FDA is still investigating Teva's generic Wellbutrin XL. |
The Motley Fool March 3, 2004 Alyce Lomax |
Biovail Gets Nailed... Again The Canadian drug maker's stock falls on downbeat guidance. |
The Motley Fool March 16, 2007 Billy Fisher |
Challenge Awaits Biovail The company's popular Wellbutrin XL will be facing generic competition soon. Biovail is currently trading 36% below its 52-week high. |
The Motley Fool November 13, 2006 Brian Lawler |
Biovail Is Getting Cheap One of the drugmaker's products could face generic competition in the next year. Investors, take note. |
Chemistry World October 5, 2012 Phillip Broadwith |
Teva pulls generic antidepressant The move was prompted by an FDA investigation into whether the generic version (Budeprion XL, made by Impax and marketed by Teva) is truly therapeutically equivalent to the branded medicine (Wellbutrin XL). |
The Motley Fool August 3, 2007 Brian Orelli |
Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note. |
The Motley Fool November 26, 2010 Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool December 11, 2006 Brian Lawler |
Biovail Gives Investors the Cash Regardless of lower forward estimates, though, it's nice to see a mature biotech rewarding shareholders, and if Biovail can sustain its dividend over the long run, it will be by far the highest-yielding mid-cap pharma stock. |
The Motley Fool August 28, 2007 Brian Orelli |
Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note. |
The Motley Fool January 19, 2011 Brian Orelli |
A Painfully Protracted Partner Depomed is in a bind. |
The Motley Fool December 26, 2007 Brian Orelli |
Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute. |
The Motley Fool July 30, 2008 Brian Orelli |
Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest. |
The Motley Fool August 3, 2004 Jeff Hwang |
Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%. |
The Motley Fool September 9, 2010 Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. |
The Motley Fool November 7, 2008 Brian Orelli |
Teva's Steady Growth Generic-drug maker Teva Pharmaceuticals has been a good defensive play during the severe downturn in the market. |
The Motley Fool July 27, 2010 Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
Financial Planning September 1, 2008 Andrew Ackerman |
SEC Probes Wachovia The Securities and Exchange Commission enforcement staff has notified Wachovia Bank that they may recommend the SEC file charges against it, as a result of an investigation into alleged anti-competitive bidding practices. |
The Motley Fool May 12, 2011 Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool December 1, 2009 Brian Orelli |
Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor. |
The Motley Fool March 4, 2005 Rich Duprey |
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails. |
The Motley Fool November 5, 2004 Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
The Motley Fool November 27, 2006 Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool February 27, 2009 Brian Orelli |
Double Approvals, Accelerated Growth Genzyme gets a pair of approvals -- one from each side of the Atlantic -- for two different products. |
The Motley Fool April 13, 2010 Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
The Motley Fool February 13, 2008 Brian Orelli |
Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted. |
The Motley Fool March 28, 2006 Charly Travers |
"60 Minutes" Blew It The venerable news show stumbles in its coverage of short selling. While some CEOs might draw attention away from their businesses' performance by invoking the short-seller boogeyman, rational investors should resist that distraction and focus on the crystal-clear fundamentals. |
The Motley Fool June 28, 2011 Eric Bleeker |
Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets. |
The Motley Fool August 10, 2010 Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool June 6, 2005 Stephen D. Simpson |
"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position. |
The Motley Fool August 29, 2008 Brian Orelli |
Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up. |
Registered Rep. May 10, 2007 Kristen French |
SEC Impostors on the Loose The SEC issued an alert to securities industry firms, warning them to keep an eye out for impostors -- individuals pretending to work for the SEC. |
The Motley Fool August 17, 2010 Travers & Jayson |
How Long Can Biovail Last? Stop obsessing about the science. |
CFO October 1, 2002 Alix Nyberg |
Regulation: Pitt and the Pendulum The kinder, gentler SEC Pitt envisioned vanished faster than you can say Arthur Andersen. Can he run a tougher, meaner agency? |
The Motley Fool August 13, 2008 Dan Dzombak |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Constellation Energy... Manitowoc... Biovail... |
The Motley Fool August 11, 2008 Rich Duprey |
The Auction-Rate Thaw Turns to a Flood Settlements by big investment banks may finally inundate the frozen market with cash. |